Target Name: NKRF
NCBI ID: G55922
Review Report on NKRF Target / Biomarker Content of Review Report on NKRF Target / Biomarker
NKRF
Other Name(s): NFKB repressing factor, transcript variant 2 | NFKB repressing factor, transcript variant 1 | NKRF variant 2 | transcription factor NRF | NRF | NFKB repressing factor | NKRF variant 1 | Protein ITBA4 | NF-kappa-B-repressing factor | NF-kappa-B-repressing factor (isoform 1) | Transcription factor NRF | NKRF_HUMAN | ITBA4 | NFkB-repressing factor

NKRF Gene: A Promising Drug Target for Cancer and Neurodegenerative Disorders

The NKRF gene, also known as NFKB repressing factor or NFKB, is a non-coding RNA molecule that plays a critical role in regulating the activity of the nuclear factor kappa B (NF-kappa-B) signaling pathway. The NF-kappa-B pathway is a well-established pathway that regulates various cellular processes, including inflammation, cell growth, and stress responses. Malf function of the NF-kappa-B pathway has been implicated in various diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. Therefore, targeting the NKRF gene is a promising strategy for developing new treatments for these diseases.

The NKRF gene was first identified in 2004 as a gene that encodes a protein that was highly expressed in various tissues and cells, including brain, spleen, and peripheral blood cells. The protein encoded by the NKRF gene was shown to interact with the NF-kappa-B signaling pathway components, including the p65 signaling molecule. This interaction between the NKRF protein and p65 led to the formation of a complex that inhibited the activity of the NF-kappa-B pathway.

The NKRF gene has four transcript variants, including transcript variant 2 (NKRF2), which is the most abundant variant. NKRF2 has been shown to function as a negative regulator of the NF-kappa-B pathway, and its expression has been implicated in the regulation of various cellular processes, including inflammation, cell growth, and stress responses.

NKRF2 has been shown to regulate the activity of several key NF-kappa-B pathway components, including the p65 protein. The NKRF2 protein has been shown to physically interact with the p65 protein and prevent its phosphorylation. This interaction between NKRF2 and p65 has important implications for the regulation of the NF-kappa-B pathway.

In addition to its role in regulating the NF-kappa-B pathway, NKRF2 has also been shown to play a role in the regulation of cellular processes that are independent of the NF-kappa-B pathway, such as cell adhesion and migration. NKRF2 has been shown to regulate the activity of several proteins that are involved in these processes, including the cadherin protein and the vimentin protein.

The NKRF gene has also been implicated in the development and progression of various diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. For example, NKRF2 has been shown to be downregulated in various types of cancer, including breast cancer and colon cancer. This downregulation of NKRF2 has been shown to contribute to the development of cancer stem cells and the maintenance of cancer cell proliferation.

In addition to its role in cancer, NKRF2 has also been implicated in the development and progression of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. NKRF2 has been shown to be involved in the regulation of immune cell function and the development of autoantibodies.

Finally, NKRF2 has also been implicated in the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. NKRF2 has been shown to be involved in the regulation of neurotransmitter synthesis and release, as well as the regulation of cellular processes that are involved in neurodegeneration.

In conclusion, the NKRF gene is a promising drug target and biomarker for the development of new treatments for various diseases. The NKRF protein has been shown to function as a negative regulator of the NF-kappa-B pathway, and its regulation of the NF-kappa-B pathway by NKRF2 is a critical step in the regulation of cellular processes that are involved in inflammation, cell growth, and stress responses. The NKRF gene has also been shown to play a role in the regulation of

Protein Name: NFKB Repressing Factor

Functions: Enhances the ATPase activity of DHX15 by acting like a brace that tethers mobile sections of DHX15 together, stabilizing a functional conformation with high RNA affinity of DHX15 (PubMed:12381793). Involved in the constitutive silencing of the interferon beta promoter, independently of the virus-induced signals, and in the inhibition of the basal and cytokine-induced iNOS promoter activity (PubMed:12381793). Also involved in the regulation of IL-8 transcription (PubMed:12381793). May also act as a DNA-binding transcription regulator: interacts with a specific negative regulatory element (NRE) 5'-AATTCCTCTGA-3' to mediate transcriptional repression of certain NK-kappa-B responsive genes (PubMed:10562553)

The "NKRF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NKRF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NKTR | NKX1-1 | NKX1-2 | NKX2-1 | NKX2-1-AS1 | NKX2-2 | NKX2-3 | NKX2-4 | NKX2-5 | NKX2-6 | NKX2-8 | NKX3-1 | NKX3-2 | NKX6-1 | NKX6-2 | NKX6-3 | NLE1 | NLGN1 | NLGN1-AS1 | NLGN2 | NLGN3 | NLGN4X | NLGN4Y | NLK | NLN | NLRC3 | NLRC4 | NLRC4 Inflammasome | NLRC5 | NLRP1 | NLRP1 Inflammasome | NLRP10 | NLRP11 | NLRP12 | NLRP13 | NLRP14 | NLRP2 | NLRP2B | NLRP3 | NLRP3 Inflammasome | NLRP3P1 | NLRP4 | NLRP5 | NLRP6 | NLRP7 | NLRP8 | NLRP9 | NLRP9P1 | NLRX1 | NMB | NMBR | NMD3 | NMDA receptor | NME1 | NME1-NME2 | NME2 | NME2P1 | NME3 | NME4 | NME5 | NME6 | NME7 | NME8 | NME9 | NMI | NMNAT1 | NMNAT2 | NMNAT3 | NMRAL1 | NMRAL2P | NMRK1 | NMRK2 | NMS | NMT1 | NMT2 | NMTRQ-TTG10-1 | NMTRQ-TTG12-1 | NMTRV-TAC1-1 | NMU | NMUR1 | NMUR2 | NNAT | NNMT | NNT | NNT-AS1 | NOA1 | NOB1 | NOBOX | NOC2L | NOC2LP2 | NOC3L | NOC4L | NOCT | NOD1 | NOD2 | NODAL | NOG | NOL10 | NOL11 | NOL12